Retatrutide Dosage: What the Clinical Trials Studied (and Why There Is No Label Yet)

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

Retatrutide dosage is one of the most searched questions about the new triple-agonist weight-loss drugs, and the honest answer is that there is no approved retatrutide dose. Retatrutide is an investigational drug. It has no FDA label, so every dose figure in circulation comes from one of two places: the published clinical trials, or sellers of unregulated "research" product. This post explains the doses that were actually studied, how the trials escalated them, and why trial doses are not a protocol.

For what retatrutide is and how it works, see the retatrutide library page.

Retatrutide Dosage in the Phase 2 Obesity Trial

The Doses That Were Studied

The main published source for retatrutide dosing is the phase 2 obesity trial, published in 2023, which randomized adults with obesity, or overweight with weight-related conditions, to once-weekly subcutaneous retatrutide or placebo for 48 weeks. Four target doses were studied: 1 mg, 4 mg, 8 mg and 12 mg once weekly.

Weight loss increased with dose. As our retatrutide vs tirzepatide vs semaglutide comparison notes, the 12 mg arm reported mean weight loss of roughly 24% at 48 weeks. That is the figure that made retatrutide a headline story.

How Escalation Worked

Like semaglutide and tirzepatide, retatrutide was not started at the target dose. Higher-dose arms began lower and stepped up at intervals, and the trial also compared different starting doses. The reason is gastrointestinal tolerability: nausea, vomiting and diarrhea in this class are concentrated during escalation, and slower escalation is the standard way to manage them.

Phase 3 and Beyond

A larger phase 3 program (TRIUMPH) is evaluating retatrutide across obesity and related conditions, and began reporting topline results in late 2025; retatrutide nonetheless remains investigational and not FDA-approved. Its doses, escalation schedules and results should be read from the published trial reports themselves. Until an FDA label exists, the phase 3 protocols describe how the drug was studied, not how it should be prescribed.

Why Trial Doses Are Not a Prescribing Protocol

No Label, No Established Dose

For an approved drug, the label turns trial evidence into instructions: a starting dose, escalation intervals, maintenance options, adjustments and contraindications. Retatrutide has none of that yet. A clinician reading the trial arms is reading research design, and there is no regulator-reviewed guidance for individual patients.

No Legitimate Compounding Pathway

Our retatrutide compounding guide sets out the regulatory position: retatrutide is not FDA-approved, is not on the 503A bulk drug substances list, and doesn't meet the conditions for legitimate 503A compounding. The shortage-era allowance that applied to semaglutide and tirzepatide doesn't extend to it, because there is no approved product to be in shortage.

The Problem With "Research" Vials

Most retatrutide dosing charts online are built around research-chemical vials: lyophilized powder of unverified identity and strength, sold "not for human use", with suggested unit conversions. The risks are specific:

• Unknown content. Identity, purity and actual quantity per vial are unverified.
• Unknown sterility. Injectable products made outside regulated facilities carry contamination risk.
• Concentration errors. When the amount in the vial is uncertain, every calculated dose is uncertain too.
• No pharmacovigilance. Adverse events go unreported and untracked.

A retatrutide "dosage chart" built on those vials has no clinical basis, however precise its numbers look.

What Clinicians Can Offer Instead

Available Incretin Therapy

Patients asking about retatrutide almost always want more weight loss than they have achieved, or expect to achieve. The available options are FDA-approved:

• Tirzepatide (Mounjaro, Zepbound): a dual GIP/GLP-1 agonist with labeled titration up to 15 mg weekly. See the tirzepatide dosage chart.
• Semaglutide (Ozempic, Wegovy; oral forms also exist): a GLP-1 agonist with an extensive evidence base.

Setting Expectations on Timing

Commercial availability of retatrutide depends on phase 3 completion and FDA review. Until then, the most useful conversation is about getting the most from available therapy: titration, adherence, nutrition, protein intake and resistance training to protect lean mass.

Retatrutide Dosage at a Glance

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner. Prescribers can start at For Providers.

Frequently Asked Questions

What is the dose of retatrutide?

There is no approved dose. The published phase 2 obesity trial studied 1 mg, 4 mg, 8 mg and 12 mg once weekly, with higher doses reached by gradual escalation. Those are trial doses, not a prescribing protocol.

What is the maximum dose of retatrutide studied?

The highest dose in the phase 2 obesity trial was 12 mg once weekly, reached by stepwise escalation. Phase 3 dosing should be read from the published phase 3 reports.

How is retatrutide dosed, weekly or daily?

In clinical trials, retatrutide was given as a once-weekly subcutaneous injection, the same schedule as semaglutide and tirzepatide.

Can a compounding pharmacy compound or supply retatrutide?

Legitimate 503A compounding doesn't extend to retatrutide. It is not FDA-approved and not on the 503A bulks list, so prescribers should confirm the regulatory basis for any retatrutide product before relying on it.

Is a retatrutide dosage chart for research vials reliable?

No. Those charts assume a vial content and purity that can't be verified. Retatrutide sold as a research chemical has no quality assurance, so any dose calculated from it is uncertain.